

Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

NF-kappaB2 p100/p52 Antibody

RRID:AB_10695537

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4882, RRID:AB_10695537

Antibody Information

URL: http://antibodyregistry.org/AB_10695537

Proper Citation: Cell Signaling Technology Cat# 4882, RRID:AB_10695537

Target Antigen: NF-kappaB2 p100/p52

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10695537, AB_10828354, AB_2153403.

Antibody Name: NF-kappaB2 p100/p52 Antibody

Description: This polyclonal targets NF-kappaB2 p100/p52

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10695537

Vendor: Cell Signaling Technology

Catalog Number: 4882

Record Creation Time: 20250819T222332+0000

Record Last Update: 20250820T020249+0000

Ratings and Alerts

No rating or validation information has been found for NF-kappaB2 p100/p52 Antibody.

No alerts have been found for NF-kappaB2 p100/p52 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ma X, et al. (2026) IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes. *Cell chemical biology*, 33(4), 553.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. *Cancer cell*.

Goyal S, et al. (2025) Bacterial ADP-heptose triggers stem cell regeneration in the intestinal epithelium following injury. *Cell stem cell*, 32(8), 1235.

Shemorry A, et al. (2025) Engineering ER γ degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. *Cell chemical biology*, 32(5), 694.

Tang D, et al. (2025) Augment proteasome inhibitor efficacy activates CD8 $^{+}$ T cell-mediated antitumor immunity in breast cancer. *Cell reports. Medicine*, 6(7), 102211.

Ghosh A, et al. (2025) Potentiation of noncanonical NF- κ B signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing. *Cell reports*, 44(12), 116616.

Zheng K, et al. (2025) Mask protein keeps NF- κ B precursor inactive by inducing a closed conformation and isolating it in biomolecular condensates. *Cell reports*, 44(9), 116225.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. *Experimental dermatology*, 34(5), e70123.

Liu L, et al. (2025) TWEAK-Fn14 signaling protects mice from pulmonary fibrosis by inhibiting fibroblast activation and recruiting pro-regenerative macrophages. *Cell reports*, 44(2), 115220.

Zhou L, et al. (2025) Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms. *Cell reports*, 44(2), 115310.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. *Cell reports*, 44(10), 116404.

Anany MA, et al. (2025) Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins. *Cell chemical biology*.

Gitlin AD, et al. (2024) N4BP1 coordinates ubiquitin-dependent crosstalk within the I κ B kinase family to limit Toll-like receptor signaling and inflammation. *Immunity*, 57(5), 973.

Yan HF, et al. (2024) Cell density impacts the susceptibility to ferroptosis by modulating IRP1-mediated iron homeostasis. *Journal of neurochemistry*, 168(7), 1359.

Domaniku-Waraich A, et al. (2024) Oncostatin M signaling drives cancer-associated skeletal muscle wasting. *Cell reports. Medicine*, 5(4), 101498.

You E, et al. (2024) Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. *Cell*, 187(25), 7232.

Lan Y, et al. (2023) IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2. *iScience*, 26(8), 107377.

Afsahi A, et al. (2023) LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. *Frontiers in immunology*, 14, 1179827.

Dardis GJ, et al. (2023) An EZH2-NF- κ B regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer. *iScience*, 26(7), 107115.

Lin XT, et al. (2023) Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. *Cell reports*, 42(7), 112812.